A Phase 1 interventional study of Test GXR and Reference GXR in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing metformin in Diabetes Mellitus — 7 open to participants now, 7 under way, 1 of them phase 3. Metformin · Diabetes Mellitus.
Among the 113 studies testing metformin in Diabetes Mellitus, this one is the 75th largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 in phase 1, and was the 96th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →7 of the 113 studies testing metformin in Diabetes Mellitus are open now, in 6 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in Nigeria
Ages 18+
Nabiqasim Industries (Pvt) Ltd · Sites in Pakistan
Ages 18–80
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 17 · Phase 3 36 · Phase 4 37
First in 1996; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 108 across the 112 interventional studies. Of the 96 that completed or were terminated, 45 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 113 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 8 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 113 studies testing metformin in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will assess the bioequivalence between single doses of GXR manufactured in Merck Nantong China (test drug) and GXR manufactured in Merck Darmstadt Germany (reference drug) under fed and fasted state in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
Drug: Test GXR · Drug: Reference GXR
Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
Drug: Test GXR · Drug: Reference GXR
Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
Drug: Test GXR · Drug: Reference GXR
Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
Drug: Test GXR · Drug: Reference GXR
Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Also known as: Metformin hydrochloride
Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Also known as: Metformin hydrochloride
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Maximum Observed Plasma Concentration (Cmax) of Metformin
Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Time to Reach Maximum Plasma Concentration of Metformin
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Apparent Terminal Half-Life (t1/2) of Metformin
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Area Under the Plasma Concentration-Time Curve From Time Tlast Extrapolated to Infinity (AUCextra) of Metformin
AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Elimination Rate Constant (Lambda z) of Metformin
Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Total Body Clearance (CL/f) of Metformin
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin
Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14 post-dose on Day 1 and Day 8; 24, 30, 36 hours post-dose on Day 2 and 9; 48 hours post-dose on Day 3 and 10
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Time from informed consent up to end of study (Day 15)
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.
Time frame: Time from informed consent up to end of study (Day 15)
Number of Participants With Clinically Significant Abnormalities in Laboratory Values
The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities in laboratory values were reported. Clinically Significance was decided by investigator.
Time frame: Time from informed consent up to end of study (Day 15)
Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings
Physical examination included assessments of the general appearance, skin and mucosa, superficial lymph nodes, head and neck, chest, abdomen, musculoskeletal, and neurological systems. Number of participants with clinically significant abnormalities in physical examination findings were reported. clinically significance was decided by investigator.
Time frame: Time from informed consent up to end of study (Day 15)
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities in 12-lead ECG findings were reported. Clinically significance was decided by investigator.
Time frame: Time from informed consent up to end of study (Day 15)
| Milestone | First Test GXR (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fasting), Then Test GXR (Fasting) | First Test GXR (Fed), Then Reference GXR (Fed) | First Reference GXR (Fed), Then Test GXR (Fed) |
|---|---|---|---|---|
| Started | 19 | 19 | 8 | 8 |
| Treated | 19 | 18 | 8 | 8 |
| Completed | 19 | 18 | 8 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Enrolled, but never treated | 0 | 1 | 0 | 0 |
| Milestone | First Test GXR (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fasting), Then Test GXR (Fasting) | First Test GXR (Fed), Then Reference GXR (Fed) | First Reference GXR (Fed), Then Test GXR (Fed) |
|---|---|---|---|---|
| Started | 19 | 18 | 8 | 8 |
| Completed | 19 | 18 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| nanogram*hour per milliliter (ng*h/mL) | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin | 3740 ± 31.5 | 3780 ± 26.2 | 5500 ± 17.1 | 5540 ± 18.7 |
Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.
| ng/mL | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Metformin | 572 ± 32.7 | 578 ± 34.2 | 519 ± 17.1 | 536 ± 16.4 |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| hours | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration of Metformin | 3.00 (1.00 to 5.00) | 4.00 (1.00 to 5.00) | 6.00 (3.00 to 10.00) | 6.00 (5.00 to 8.00) |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by lambda z.
| hours | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Metformin | 5.80 ± 63.7 | 5.56 ± 58.4 | 5.34 ± 65.1 | 5.37 ± 99.8 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ lambda z, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and lambda z is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| ng*h/mL | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Metformin | 3890 ± 29.4 | 3980 ± 25.0 | 5630 ± 17.2 | 5750 ± 19.2 |
AUCextra% was defined as area under the curve from time tlast extrapolated to infinity as percentage of AUC 0-infinity. Here, tlast is the last sampling time at which the concentration is at or above the lower limit of quantification.
No measurements were reported for this outcome.
Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
| liter per hour | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Total Body Clearance (CL/f) of Metformin | 128 ± 29.4 | 126 ± 25.0 | 88.9 ± 17.2 | 87.0 ± 19.2 |
Vz/f is defined as the distribution of a study drug between plasma and the rest of the body after oral dosing.
| liter | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Apparent Volume of Distribution at After Extravascular Administration (Vz/f) of Metformin | 1070 ± 75.6 | 1010 ± 61.1 | 684 ± 65.8 | 674 ± 93.7 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. An AE was considered as 'treatment emergent' if it occurred after the first drug administration of each period or if it was present prior to drug administration but exacerbated after the drug administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| TEAEs | 10 | 11 | 3 | 4 |
| Serious TEAEs | 0 | 0 | 0 | 0 |
Vital sign assessment included blood pressure, pulse rate, body temperature and respiration (frequency per minute). Number of participants with clinically significant abnormalities in vital signs were reported. Clinically significance was decided by investigator.
| Participants | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Vital Signs | 0 | 0 | 0 | 0 |
The laboratory measurements included hematology, blood chemistry and urinalysis. Number of participants with clinically significant abnormalities in laboratory values were reported. Clinically Significance was decided by investigator.
| Participants | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Values | 0 | 0 | 0 | 0 |
Physical examination included assessments of the general appearance, skin and mucosa, superficial lymph nodes, head and neck, chest, abdomen, musculoskeletal, and neurological systems. Number of participants with clinically significant abnormalities in physical examination findings were reported. clinically significance was decided by investigator.
| Participants | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Physical Examination Findings | 0 | 0 | 0 | 0 |
The 12-lead ECG recordings were obtained after 5 minutes of rest in a semi-supine position. ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, QT and QTc intervals. Number of participants with clinically significant abnormalities in 12-lead ECG findings were reported. Clinically significance was decided by investigator.
| Participants | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings | 0 | 0 | 0 | 0 |
Collected over Time from informed consent up to end of study (Day 15). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test GXR (Fasting) | 0/37 (0%) | 0/37 (0%) | 10/37 (27%) |
| Reference GXR (Fasting) | 0/37 (0%) | 0/37 (0%) | 11/37 (29.7%) |
| Test GXR (Fed) | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Reference GXR (Fed) | 0/16 (0%) | 0/16 (0%) | 4/16 (25%) |
| Event | Test GXR (Fasting) | Reference GXR (Fasting) | Test GXR (Fed) | Reference GXR (Fed) |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/37 | 6/37 | 1/16 | 3/16 |
| Upper respiratory tract infectionInfections and infestations | 0/37 | 3/37 | 0/16 | 0/16 |
| Abdominal painGastrointestinal disorders | 2/37 | 0/37 | 1/16 | 0/16 |
| NauseaGastrointestinal disorders | 1/37 | 0/37 | 0/16 | 1/16 |
| Mouth ulcerationGastrointestinal disorders | 0/37 | 0/37 | 0/16 | 1/16 |
| VomitingGastrointestinal disorders | 0/37 | 0/37 | 0/16 | 1/16 |
| Oral herpesInfections and infestations | 0/37 | 0/37 | 0/16 | 1/16 |
| White blood cell count decreasedInvestigations | 1/37 | 0/37 | 1/16 | 0/16 |
| Electrocardiogram ST segment abnormalInvestigations | 0/37 | 0/37 | 1/16 | 0/16 |
| MalaiseGeneral disorders | 0/37 | 0/37 | 0/16 | 1/16 |
Safety population included all participants who received at least 1 dose of investigational medicinal product (IMP).
| Age, Continuous(years) | First Test GXR (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fasting), Then Test GXR (Fasting) | First Test GXR (Fed), Then Reference GXR (Fed) | First Reference GXR (Fed), Then Test GXR (Fed) | Total |
|---|---|---|---|---|---|
| Mean | 31.5 ± 8.00 | 33.5 ± 8.79 | 32.6 ± 7.13 | 35.8 ± 11.15 | 33.0 ± 8.55 |
| Sex: Female, Male(Participants) | First Test GXR (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fasting), Then Test GXR (Fasting) | First Test GXR (Fed), Then Reference GXR (Fed) | First Reference GXR (Fed), Then Test GXR (Fed) | Total |
|---|---|---|---|---|---|
| Female | 6 | 7 | 3 | 3 | 19 |
| Male | 13 | 11 | 5 | 5 | 34 |
| Race (NIH/OMB)(Participants) | First Test GXR (Fasting), Then Reference GXR (Fasting) | First Reference GXR (Fasting), Then Test GXR (Fasting) | First Test GXR (Fed), Then Reference GXR (Fed) | First Reference GXR (Fed), Then Test GXR (Fed) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 19 | 18 | 8 | 8 | 53 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Nov 2018, 1 month.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 1 month is below that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Merck KGaA, Darmstadt, Germany →